| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | pncA |
| Uniprot No | P21369 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-213aa |
| 氨基酸序列 | MPPRALLLVDLQNDFCAGGALAVPEGDSTVDVANRLIDWCQSRGEAVIASQDWHPANHGSFASQHGVEPYTPGQLDGLPQTFWPDHCVQNSEGAQLHPLLHQKAIAAVFHKGENPLVDSYSAFFDNGRRQKTSLDDWLRDHEIDELIVMGLATDYCVKFTVLDALQLGYKVNVITDGCRGVNIQPQDSAHAFMEMSAAGATLYTLADWEETQG |
| 预测分子量 | 30.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于pncA重组蛋白的3篇参考文献及其摘要概述：
1. **"Expression and purification of recombinant Mycobacterium tuberculosis pncA for pyrazinamidase activity analysis"**
- **作者**: Scorpio et al.
- **摘要**: 该研究描述了结核分枝杆菌pncA基因的克隆、重组表达及纯化，分析了重组蛋白的吡嗪酰胺酶活性，并探讨了耐药相关突变对酶功能的影响。
2. **"Crystal structure of the pyrazinamidase from Mycobacterium tuberculosis: Insights into drug resistance"**
- **作者**: Petrella et al.
- **摘要**: 通过X射线晶体学解析了重组pncA蛋白的三维结构，揭示了吡嗪酰胺耐药相关突变的结构基础，为理解药物活化机制提供依据。
3. **"Functional characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates"**
- **作者**: Jureen et al.
- **摘要**: 利用重组表达的pncA蛋白评估了临床耐药菌株中的多种突变，发现特定氨基酸替换导致酶活性丧失，直接关联吡嗪酰胺耐药性。
---
以上文献涵盖了pncA重组蛋白的制备、结构解析及耐药性功能研究，均为该领域的代表性工作。
**Background of pncA Recombinant Protein**
The *pncA* gene encodes pyrazinamidase (PZase), an enzyme critical for activating the prodrug pyrazinamide (PZA), a first-line antituberculosis agent. In *Mycobacterium tuberculosis* (Mtb), PZase converts PZA into its active form, pyrazinoic acid (POA), which disrupts bacterial membrane potential and energy metabolism. Mutations in *pncA* are the primary cause of PZA resistance, observed in over 70% of clinically resistant Mtb strains. Studying the *pncA* gene and its protein product is thus essential for understanding drug resistance mechanisms and improving tuberculosis (TB) treatment.
Recombinant pncA protein, produced via heterologous expression systems (e.g., *E. coli*), enables functional and structural analyses of wild-type and mutant PZase variants. This recombinant approach allows researchers to characterize enzymatic activity, assess the impact of specific mutations on drug activation, and identify resistance-associated genetic changes. Additionally, recombinant pncA serves as a tool for developing rapid diagnostics, such as enzymatic assays or antigen-based tests, to detect PZA resistance without time-consuming culture methods.
Beyond clinical applications, pncA recombinant protein aids in drug discovery by facilitating high-throughput screening of PZA analogs or adjuvants that restore efficacy against resistant strains. Structural studies using recombinant PZase have revealed insights into its catalytic mechanism and mutation-induced conformational changes, guiding rational drug design.
Overall, pncA recombinant protein is pivotal in addressing TB drug resistance, advancing diagnostic innovation, and informing therapeutic strategies against one of the world’s deadliest infectious diseases. Its study bridges genetic research, clinical microbiology, and drug development, highlighting its multidisciplinary significance in global health.
×
